- Home
- HUYA vs AGMB Comparison
HUYA vs AGMB Comparison
Compare HUYA & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HUYA | AGMB |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | China | Belgium |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 773.0M | 677.9M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | HUYA | AGMB |
|---|---|---|
| Price | $3.51 | $13.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $3.50 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 1.4M | 95.1K |
| Earning Date | 03-17-2026 | 06-16-2026 |
| Dividend Yield | ★ 71.97% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.78 | N/A |
| Revenue Next Year | $11.69 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.21 | $13.20 |
| 52 Week High | $4.93 | $17.45 |
Technical Indicators
Market Signals| Indicator | HUYA | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 46.65 | 41.39 |
| Support Level | $3.24 | $13.43 |
| Resistance Level | $3.85 | $16.16 |
| Average True Range (ATR) | 0.16 | 1.24 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 62.63 | 16.22 |
Price Performance
Historical ComparisonAbout HUYA HUYA Inc. American depositary shares each representing one ordinary share
Huya, officially became independent in 2016 and headquartered in Guangzhou, operates live streaming platform focused on games, esports, and interactive entertainment, and also provides game-related services such as distribution and in-game item sales. Its main livestreaming platforms include Huya Live in China and Nimo TV outside of China. As of 2024, Huya was a subsidiary of Tencent, which owned 67% of its equity stake and held 95% of the voting power.
About AGMB AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.